Daewoong / NABOTA

• 1945 Established in South Korea
• 1973 Listed on the Korean Stock Exchange
• $800M Annual revenue as of 2015**
• 1,500+ Employees as of 2016.4Q
• 28 Affiliates in healthcare business
• 7 Branch operations in Asia & US
• 6 Manuf. Sites: Korea, China, Indonesia
• 5 R&D centers: Korea, China, India, US
• Daewoong Pharmaceutical Pharma Total Sales: USD 884 million
• Daewoong Group Group Total Sales: USD 1.6 billion

---

BioFormula Aesthetic Products line

• Brand new Fillers BDDE based, medium and superior,EVANTHIA 20 and EVANTHIA 25;
• Fillers DVS based, thin, medium and deep, AURALYA 1, AURALYA 2 and AURALYA 3;
• Inject able Revitalize CE marked, light, medium, strong, JALUCOMPLEX 1, JALUCOMPLEX 2 and JALUCOMPLEX 3;
• Mesotherapy ready to use sterile solutions for face (revitalizing, anti-aging, toning results) AMINO JAL, AMINO JAL STRONG and many more;
• Mesotherapy ready to use sterile solutions for body (draining, lipo- reducing results); LIPOLISE, LIPOTENE
• 35% TCA peeling; PEEL TOUCH, a unique and fortified peeling formulation with immediate lifting effects;
• Peelings for professional use.